President & CEO, Cardiff Oncology
Mani Mohindru, Ph.D., has served as Cardiff Oncology’s interim CEO since January 2026, president and CEO since late March 2026 and has been a director since 2021. She is a co-founder and board chair of Roshon Therapeutics, an early-stage, private biotech company developing antibodies for the treatment of cancer and inflammatory diseases.
Mani’s prior executive roles include serving as CEO of CereXis, CEO and board director of Novasenta, CFO and chief strategy officer of Cara Therapeutics and as chief strategy officer at Curis. Prior to her leadership roles in the biotechnology industry, Mani spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. Mani serves on the board of directors of CytomX Therapeutics and previously served on the board of SAB Biotherapeutics. She earned her Ph.D. in neuroscience from Northwestern University and her master’s and bachelor’s degrees from the All India Institute of Medical Sciences.